Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Reverses Obesity-Related Winning Streak, Diving On Light Sales

Novo is restricting some doses of Wegovy in the U.S., the company said Thursday. Novo Nordisk stock fell on light second-quarter sales.

Investors Business Daily

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

Why The Weight-Loss Bonanza Catapulted Lilly And Novo, But Hammered Dexcom And Others

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Fortune

AI Stocks Lead These 5 Names Near Buy Points

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Investors Business Daily

Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli Lilly

Pfizer stock toppled Monday after the company tossed out a potential diabetes and weight-loss drug that leads to elevated liver enzymes.

Investors Business Daily

Ozempic maker now wants to keep people from becoming obese in the first place

Novo Nordisk is investing in obesity prevention, the 'real big frontier' of weight loss.

Fortune

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

Why You Should Go Overweight On Novo Nordisk Stock

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.

Barchart

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

Businessweek

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Investors Business Daily

Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook

Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $2.7 Billion Deal

Novo Nordisk stock popped Wednesday after the drugmaker inked a $2.7 billion deal that bolsters its diabetes and obesity treatments.

The Guardian - UK

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

Investors Business Daily

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Novo Nordisk stock popped Friday after higher doses of its popular drug, semaglutide, led to greater weight loss in diabetes patients.

Tribune News Service

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Novo Nordisk A/S replenished supplies of Ozempic, a treatment for diabetes, after social media-driven enthusiasm over the drug’s use for weight loss led to six months of shortages.

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

The Independent UK

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations